Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 3, 2011, Pages 276-280

  Goel, Shom ^a   Simes, R John ^a,b   Beith, Jane M ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biomarkers; Cardiotoxicity; N terminal pro B type natriuretic peptide; Trastuzumab; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; DOXORUBICIN; EPIRUBICIN; TRASTUZUMAB; TROPONIN I;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LIMIT OF DETECTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARDIOMYOPATHIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEART FUNCTION TESTS; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TROPONIN I;

EID: 80052197182     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01422.x     Document Type: Article

References (23)

1. Jones AL, Barlow M, Barrett-Lee PJ etal. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009; 100: 684-92.
2. Tan-Chiu E, Yothers G, Romond E etal. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-19.
3. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25: 3525-33.
4. Rastogi P, Jeong J, Geyer CE etal. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) versus AC→T with trastuzumab(H). J Clin Oncol ASCO Annual Meeting Proceedings, Part 1 2007; 25: 513.
5. Meinardi MT, van Veldhuisen DJ, Gietema JA etal. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746-53.
6. Perik PJ, De Vries EG, Boomsma F etal. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. Anticancer Res 2005; 25: 3651-7.
7. Cardinale D, Sandri MT, Colombo A etal. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-54.
8. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900-2.
9. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002; 25: 301-11.
10. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-9.
11. Cardinale D, Colombo A, Sandri MT etal. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-81.
12. Kutteh L, Hobday T, Jaffe A. A correlative study of cardiac biomarkers and left ventricular ejection fraction from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for Her-2 positive breast cancer. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part 1; 25: 570.
13. Perik PJ, Lub-De Hooge MN, Gietema JA etal. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24: 2276-82.
14. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002; 87: 97-8.
15. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-68.
16. Silver MA, Pisano C. High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. Congest Heart Fail 2003; 9: 127-32.
17. Snowden JA, Hill GR, Hunt P etal. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-13.
18. US National Institutes of Health. Cardiotoxicity of adjuvant trastuzumab (CATS). 2009. [Cited 8 July 2011.] Available from URL:.
19. US National Institutes of Health. Evaluating the effect of candesartan versus placebo in prevention of trastuzumab-associated cardiotoxicity. 2007. [Cited 8 July 2011.] Available from URL:.
20. US National Institutes of Health. Early detection and prediction of chemotherapy induced cardiac toxicity in breast cancer patients. 2008. [Cited 8 July 2011.] Available from URL:.
21. US National Institutes of Health. BETH study: treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizuma.2008. [Cited 7 Aug 2009.] Available from URL:.
22. US National Institutes of Health. Side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.2008. [Cited 7 Aug 2009.] Available from URL:.
23. Beauclair S, Formento P, Fischel JL etal. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 2007; 18: 1335-41.